SCHEMBL3618447

SCHEMBL3618447

CCOC(=O)c1cc2cc(OCc3ccccc3)ccc2o1

nearest known ligand 0.62

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAOB P27338 2/20 0.62
MEN1 O00255 1/20 0.58
HSP90AA1 P07900 1/20 0.58
KMT2A Q03164 1/20 0.58
CASP3 P42574 1/20 0.56
SENP8 Q96LD8 1/20 0.56
SENP7 Q9BQF6 1/20 0.56
SENP6 Q9GZR1 1/20 0.56
L3MBTL1 Q9Y468 2/20 0.54
PPARG P37231 1/20 0.51
MAPT P10636 2/20 0.51
ESR1 P03372 1/20 0.50
PKM P14618 1/20 0.50
KDM4E B2RXH2 1/20 0.50
ALDH1A1 P00352 1/20 0.50
CASP1 P29466 1/20 0.50
CASP7 P55210 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL744596 0.90 MAOB (0.76) MAOBMEN1HSP90AA1KMT2AMAPT
SCHEMBL3589538 0.86 MAOB (0.84) MAOBMEN1HSP90AA1KMT2AMAPT
SCHEMBL16490915 0.85 CASP3 (0.64) MAOBMEN1KMT2ACASP3SENP8
SCHEMBL4519057 0.84 PIM1 (0.58) MAOBMEN1KMT2ACASP3SENP8
SCHEMBL18591911 0.84 MAOB (0.52) MAOBMEN1KMT2AMAPTKDM4E
SCHEMBL18611964 0.84 MAOB (0.52) MAOBALDH1A1
SCHEMBL20742894 0.82 CASP3 (0.54) MAOBMEN1KMT2ACASP3SENP8
SCHEMBL8118515 0.82 MAOB (0.55) MAOBMEN1KMT2AMAPTKDM4E
SCHEMBL648621 0.82 MAOB (0.70) MAOBCASP3SENP7MAPTKDM4E
SCHEMBL26693541 0.82 ALOX5 (0.58) MAOBMEN1KMT2ACASP3SENP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250228944-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS ARVINAS OPERATIONS, INC. 2025-07-17 US disclosed
US-12171831-B2 Compounds and methods for the targeted degradation of bromodomain- containing proteins ARVINAS OPERATIONS, INC. (US) 2024-12-24 US disclosed
US-20230263893-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS ARVINAS OPERATIONS, INC. 2023-08-24 US disclosed
US-20230263893-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS ARVINAS OPERATIONS, INC. 2023-08-24 US disclosed
US-11554171-B2 Compounds and methods for the targeted degradation of bromodomain-containing proteins ARVINAS OPERATIONS, INC. (US) 2023-01-17 US disclosed
US-20210187108-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS ARVINAS OPERATIONS, INC. 2021-06-24 US disclosed
US-20210187108-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS ARVINAS OPERATIONS, INC. 2021-06-24 US disclosed
US-10772962-B2 Compounds and methods for the targeted degradation of bromodomain-containing proteins ARVINAS OPERATIONS, INC. (US) 2020-09-15 US disclosed
US-10772962-B2 Compounds and methods for the targeted degradation of bromodomain-containing proteins ARVINAS OPERATIONS, INC. (US) 2020-09-15 US disclosed
EP-3337476-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS Arvinas, Inc. (US) 2018-06-27 EP disclosed
US-7579488-B2 Vitamin D receptor modulators ELI LILLY AND COMPANY (US) 2009-08-25 US disclosed
US-20090062348-A1 Antifungal Agent Containing Pyridine Derivative EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-03-05 US disclosed
US-20090062348-A1 Antifungal Agent Containing Pyridine Derivative EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-03-05 US disclosed
US-20090062348-A1 Antifungal Agent Containing Pyridine Derivative EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-03-05 US disclosed
EP-1864980-A1 ANTIFUNGAL AGENT CONTAINING PYRIDINE DERIVATIVE Eisai R&D Management Co., Ltd. (JP) 2007-12-12 EP disclosed
US-20070106095-A1 Vitamin d receptor modulators ELI LILLY AND COMPANY 2007-05-10 US disclosed
US-20070106095-A1 Vitamin d receptor modulators ELI LILLY AND COMPANY 2007-05-10 US disclosed
US-20070106095-A1 Vitamin d receptor modulators ELI LILLY AND COMPANY 2007-05-10 US disclosed
EP-1687289-A1 VITAMIN D RECEPTOR MODULATORS ELI LILLY AND COMPANY (US) 2006-08-09 EP disclosed
WO-2005051938-A1 VITAMIN D RECEPTOR MODULATORS ELI LILLY AND COMPANY (US) 2005-06-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10772962-B2 Compounds and methods for the targeted degradation of bromodomain-containing proteins BRPF3, STUB1, BRDT MAOB 2860/4885MEN1 2783/4885HSP90AA1 627/4885
US-20070106095-A1 Vitamin d receptor modulators VDR, CYP2R1, CYP24A1 MAOB 4810/4885MEN1 3024/4885HSP90AA1 1639/4885
US-20090062348-A1 Antifungal Agent Containing Pyridine Derivative ERG28, SQOR, CYP51A1 MAOB 710/4885MEN1 2058/4885HSP90AA1 849/4885
US-11554171-B2 Compounds and methods for the targeted degradation of bromodomain-containing proteins BRPF3, STUB1, BRDT MAOB 2860/4885MEN1 2783/4885HSP90AA1 627/4885
US-20210187108-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS BRPF3, STUB1, BRDT MAOB 2860/4885MEN1 2783/4885HSP90AA1 627/4885
US-12171831-B2 Compounds and methods for the targeted degradation of bromodomain- containing proteins BRPF3, STUB1, BRDT MAOB 2860/4885MEN1 2783/4885HSP90AA1 627/4885
US-20230263893-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS BRPF3, STUB1, BRDT MAOB 2860/4885MEN1 2783/4885HSP90AA1 627/4885
US-20250228944-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS BRPF3, STUB1, BRDT MAOB 2860/4885MEN1 2783/4885HSP90AA1 627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.